Zurcher Kantonalbank Zurich Cantonalbank Has $27.08 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 293.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 222,518 shares of the medical equipment provider’s stock after buying an additional 165,937 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.11% of Zimmer Biomet worth $27,080,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Clear Street Markets LLC bought a new stake in Zimmer Biomet during the 4th quarter worth about $27,000. Dark Forest Capital Management LP bought a new stake in Zimmer Biomet during the 1st quarter worth about $35,000. Lazard Asset Management LLC raised its holdings in Zimmer Biomet by 70.5% during the 3rd quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 117 shares during the last quarter. Activest Wealth Management raised its holdings in Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 275 shares during the last quarter. Finally, KB Financial Partners LLC bought a new stake in Zimmer Biomet during the 1st quarter worth about $49,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the subject of a number of recent analyst reports. Raymond James upped their price target on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Truist Financial upped their price target on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research note on Friday, February 9th. StockNews.com cut Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. JPMorgan Chase & Co. upped their price target on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Finally, Evercore ISI upped their price target on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Trading Down 0.6 %

NYSE ZBH opened at $121.30 on Thursday. The company has a market cap of $24.92 billion, a PE ratio of 24.81, a PEG ratio of 2.24 and a beta of 1.01. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The stock has a 50 day moving average of $126.47 and a 200-day moving average of $119.10.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.88 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is 19.63%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.